Your browser doesn't support javascript.
loading
Nonclinical pharmacodynamics of boron neutron capture therapy using direct intratumoral administration of a folate receptor targeting novel boron carrier.
Tsujino, Kohei; Kashiwagi, Hideki; Nishimura, Kai; Fujikawa, Yoshiki; Kayama, Ryo; Fukuo, Yusuke; Hiramatsu, Ryo; Nonoguchi, Naosuke; Takata, Takushi; Tanaka, Hiroki; Suzuki, Minoru; Hu, Naonori; Ono, Koji; Wanibuchi, Masahiko; Nakai, Kei; Nakamura, Hiroyuki; Kawabata, Shinji.
Afiliación
  • Tsujino K; Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.
  • Kashiwagi H; Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.
  • Nishimura K; Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, Japan.
  • Fujikawa Y; Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.
  • Kayama R; Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.
  • Fukuo Y; Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.
  • Hiramatsu R; Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.
  • Nonoguchi N; Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.
  • Takata T; Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennan-gun, Japan.
  • Tanaka H; Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennan-gun, Japan.
  • Suzuki M; Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennan-gun, Japan.
  • Hu N; Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.
  • Ono K; Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.
  • Wanibuchi M; Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.
  • Nakai K; Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Nakamura H; Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, Japan.
  • Kawabata S; Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.
Neurooncol Adv ; 6(1): vdae062, 2024.
Article en En | MEDLINE | ID: mdl-38770220
ABSTRACT

Background:

Boron neutron capture therapy (BNCT) is a precise particle radiation therapy known for its unique cellular targeting ability. The development of innovative boron carriers is crucial for the advancement of BNCT technologies. Our previous study demonstrated the potential of PBC-IP administered via convection-enhanced delivery (CED) in an F98 rat glioma model. This approach significantly extended rat survival in neutron irradiation experiments, with half achieving long-term survival, akin to a cure, in a rat brain tumor model. Our commitment to clinical applicability has spurred additional nonclinical pharmacodynamic research, including an investigation into the effects of cannula position and the time elapsed post-CED administration.

Methods:

In comprehensive in vivo experiments conducted on an F98 rat brain tumor model, we meticulously examined the boron distribution and neutron irradiation experiments at various sites and multiple time intervals following CED administration.

Results:

The PBC-IP showed substantial efficacy for BNCT, revealing minimal differences in tumor boron concentration between central and peripheral CED administration, although a gradual decline in intratumoral boron concentration post-administration was observed. Therapeutic efficacy remained robust, particularly when employing cannula insertion at the tumor margin, compared to central injections. Even delayed neutron irradiation showed notable effectiveness, albeit with a slightly reduced survival period. These findings underscore the robust clinical potential of CED-administered PBC-IP in the treatment of malignant gliomas, offering adaptability across an array of treatment protocols.

Conclusions:

This study represents a significant leap forward in the quest to enhance BNCT for the management of malignant gliomas, opening promising avenues for clinical translation.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Neurooncol Adv Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Neurooncol Adv Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido